-

AGTI Investor Notice: Robbins LLP Reminds Shareholders it is Investigating the Acquisition of Agiliti Inc. by THL Partners

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Agiliti, Inc. (NYSE: AGTI) by private equity firm Thomas H. Lee Partners, L.P. ("THL"). Under the terms of the agreement, Agiliti stockholders will receive $10.00 in cash for each share of Agiliti common stock owned.

If you own shares of Agiliti, Inc. click here.

Is the Proposed Acquisition Best for Agiliti, Inc. (AGTI) and its Shareholders?

On February 26, 2024, Agiliti announced a deal to be acquired by THL. According to the Proxy Statement, Agiliti's board of directors approved the merger agreement for $10.00 per share in cash. The deal is valued at approximately $2.5 billion and is expected to close in the first half of 2024. Robbins LLP is concerned that Agiliti's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of Agiliti, Inc. (AGTI) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion in value for shareholders. To be notified if a class action against Agiliti, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AGTI

Release Summary
Robbins LLP is investigating the acquisition of Agiliti Inc. (AGTI) by THL Partners
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800)...

Investor Notice: Robbins LLP Informs Investors of the Gemini Space Station, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gemini Space Station, Inc. (NASDAQ: GEMI) Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini Space Station, Inc. securities between September 12, 2025 and February 17, 2026. Gemini was founded to develop and operate a cryptocurrency platform. For more information, s...

uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? September 24, 2025 – October 31, 2025 W...
Back to Newsroom